Item 7.01 Regulation FD Disclosure.

Agios Pharmaceuticals, Inc. ("Agios") is filing this Current Report on Form 8-K to furnish its historical consolidated financial statements and the notes thereto previously included in its Annual Report on Form 10-K for the fiscal years ended December 31, 2019 and 2018 (the "Prior 10-K") filed with the Securities and Exchange Commission on February 19, 2020 (such financial statements and notes thereto, the "2018-2019 Financial Statements"). The 2018-2019 Financial Statements, furnished as Exhibit 99.1 to this Current Report, are consistent in all respects with the financial statements for such periods included in the Prior 10-K. This Current Report does not reflect events occurring after February 19, 2020, the filing date of the Prior 10-K, and does not modify or update the disclosures set forth in the Prior 10-K in any way.

Agios expects to incorporate by reference the 2018-2019 Financial Statements in its proxy statement to be filed in connection with its previously announced sale of specified assets related to its oncology business. The 2018-2019 Financial Statements are being furnished solely for such purpose.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit
  No.       Description

99.1          The consolidated financial statements of Agios Pharmaceuticals, Inc.
            and its subsidiaries as of December 31, 2019 and 2018, including the
            consolidated balance sheets and the related consolidated statements of
            operations, of comprehensive loss, of stockholders' equity and of cash
            flows for the years then ended, including the related notes

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses